NCT05635370 is a clinical trial of Pentoxifylline in Peripheral Artery Disease, sponsored by Brigham and Women's Hospital.

Who is sponsoring NCT05635370?

NCT05635370 is sponsored by Brigham and Women's Hospital.

What drugs are being tested in NCT05635370?

Interventions in NCT05635370: Pentoxifylline, Cilostazol.

What condition does NCT05635370 study?

NCT05635370 studies Peripheral Artery Disease.

Is NCT05635370 still recruiting?

NCT05635370 is currently completed. Last updated 11 August 2025.

Are results published for NCT05635370?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-08-11 · How we verify

NCT05635370

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol

Completed Results posted Last updated 11 August 2025

What this trial tests

trial testing Pentoxifylline in Peripheral Artery Disease in 10,398 participants. Completed in 31 December 2023.

Timeline

1 November 2022

Primary endpoint
7 July 2023

31 December 2023

Quick facts

Lead sponsor	Brigham and Women's Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	10,398
Start date	1 November 2022
Primary completion	7 July 2023
Estimated completion	31 December 2023
Sites	1 location across United States

Drugs / interventions tested

Pentoxifylline — full drug profile →
Cilostazol (CILOSTAZOL) — full drug profile →

Conditions studied

Peripheral Artery Disease — all drugs for Peripheral Artery Disease →

Sponsor

Brigham and Women's Hospital

Who can join

65 and older, any sex, with Peripheral Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Time to Dementia Onset Primary · Median follow up times: 1) 180 days (exp), 170 days (ref) 2) 677 days (exp), 612 days (ref) 3) 211 days (exp), 173 days (ref) 4) 180 days (exp), 171 days (ref)

Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.

Analysis 1

Group	Value	95% CI
Pentoxifylline	28.1	20.2 – 38.2
Cilostazol	32.6	23.5 – 44.0

Analysis 2

Group	Value	95% CI
Pentoxifylline	37.9	28.4 – 49.6
Cilostazol	44.8	34.2 – 57.7

Analysis 3

Group	Value	95% CI
Pentoxifylline	30.8	18.8 – 47.6
Cilostazol	43.9	28.9 – 63.9

Analysis 4

Group	Value	95% CI
Pentoxifylline	5.2	2.3 – 10.3
Cilostazol	10.0	5.3 – 17.2

Sponsor's own description

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Population-Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study.
Desai RJ, Varma VR, Mahesri M, Lee SB, et al · · 2025 · cited 4× · PMID 39935003 · DOI 10.1002/cpt.3583

Verify or expand the search:

Other trials of Pentoxifylline

Trials testing the same drug.

NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT07349472 — Pentoxifylline in Patients With Ulcerative Colitis · Phase 2 · recruiting
NCT07086794 — Cocaine and Pentoxifylline (BED IN 47) · EARLY_PHASE1 · recruiting
NCT06912763 — Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-contro · Phase 2 · recruiting
NCT07088328 — Nephroprotection Following Perinatal Asphyxia: Randomized Controlled Trial · NA · not yet recruiting

Other recruiting trials for Peripheral Artery Disease

Currently open trials in the same condition.

NCT07374601 — The Value of Super-resolution Ultrasound Imaging for Peripheral Artery Disease · recruiting
NCT06686121 — Improving Mobility After Revascularization in Peripheral Artery Disease · Phase 3 · recruiting
NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT07012070 — Improving Walking Performance in Patients With Peripheral Artery Disease Through Wearable Activity Trackers · NA · recruiting

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05635370 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
Last refreshed: 11 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05635370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing